Dupilumab, a simple pre-filled pen that people inject themselves with every two weeks, is the first biologic that targets both the symptoms of COPD and an underlying cause of the disease. It brings ...
The treatment has been approved for NHS use, offering new hope to the nearly 12,000 people in England living with lupus ...
Thousands of people living with advanced prostate cancer will have access to a life-extending new treatment that can be taken at home from today (Friday, 23 January). NICE has recommended talazoparib ...
Accessed via the internet, the online self-help programme is for people who binge eat, particularly those with bulimia nervosa, binge eating disorder, and similar eating problems. It's designed for ...
An online therapy programme can be used to help people aged 16 and over with eating disorders whilst they wait for specialist NHS treatment, an independent NICE has said. As Sam Roberts prepared to ...
Amivantamab with lazertinib for untreated EGFR mutation-positive advanced non-small-cell lung cancer
There are simple discount patient access schemes for amivantamab (Rybrevant) and lazertinib (Lazcluze). NHS organisations can get details on the Commercial Access and Pricing (CAP) Portal. Non-NHS ...
NICE has developed tools and resources, in association with relevant stakeholders, to help organisations put this guidance into practice. The evidence generation plan gives further information on the ...
Pressure ulcer prevention: pressure ulcer risk assessment and prevention, including the use of pressure-relieving devices (beds, mattresses and overlays) for the prevention of pressure ulcers in ...
Osteoporosis: risk assessment, treatment, and fragility fracture prevention (update) Draft guidance consultation NICE guideline 23 February 2026 Enfortumab vedotin with pembrolizumab for neoadjuvant ...
Evidence-based recommendations on caplacizumab (Cablivi) with plasma exchange and immunosuppression for treating acute acquired thrombotic thrombocytopenic purpura in adults, and in young people aged ...
Evidence-based recommendations on secukinumab (Cosentyx) for moderate to severe plaque psoriasis in children and young people aged 6 to 17 years. Next review: This guidance will be reviewed if there ...
Guidance Standards and indicators Clinical Knowledge Summaries (CKS) British National Formulary (BNF) BNF for Children (BNFC) Life sciences Library and knowledge services What NICE does Implementing ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results